• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于免疫基因组图谱分析的透明细胞肾细胞癌预后预测

Prediction of clear cell renal cell carcinoma prognosis based on an immunogenomic landscape analysis.

作者信息

Wang Chengwei, Zhang Xi, Zhu Shiqing, Hu Bintao, Deng Zhiyao, Feng Huan, Liu Bo, Luan Yang, Liu Zhuo, Wang Shaogang, Liu Jihong, Wang Tao, Wu Yue

机构信息

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.

Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.

出版信息

Heliyon. 2024 Aug 13;10(16):e36156. doi: 10.1016/j.heliyon.2024.e36156. eCollection 2024 Aug 30.

DOI:10.1016/j.heliyon.2024.e36156
PMID:39247280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11379575/
Abstract

Immune cell infiltration and tumor-related immune molecules play key roles in tumorigenesis and tumor progression. The influence of immune interactions on the molecular characteristics and prognosis of clear cell renal cell carcinoma (ccRCC) remains unclear. A machine learning algorithm was applied to the transcriptome data from The Cancer Genome Atlas database to determine the immunophenotypic and immunological characteristics of ccRCC patients. These algorithms included single-sample gene set enrichment analyses and cell type identification. Using bioinformatics techniques, we examined the prognostic potential and regulatory networks of immune-related genes (IRGs) involved in ccRCC immune interactions. Fifteen IRGs (CCL7, CHGA, CMA1, CRABP2, IFNE, ISG15, NPR3, PDIA2, PGLYRP2, PLA2G2A, SAA1, TEK, TGFA, TNFSF14, and UCN2) were identified as prognostic IRGs associated with overall survival and were used to construct a prognostic model. The area under the receiver operating characteristic curve at 1 year was 0.927; 3 years, 0.822; and 5 years, 0.717, indicating good predictive accuracy. Molecular regulatory networks were found to govern immune interactions in ccRCC. Additionally, we developed a nomogram containing the model and clinical characteristics with high prognostic potential. By systematically examining the sophisticated regulatory mechanisms, molecular characteristics, and prognostic potential of ccRCC immune interactions, we provided an important framework for understanding the molecular mechanisms of ccRCC and identifying new prognostic markers and therapeutic targets for future research.

摘要

免疫细胞浸润和肿瘤相关免疫分子在肿瘤发生和肿瘤进展中起关键作用。免疫相互作用对透明细胞肾细胞癌(ccRCC)分子特征和预后的影响仍不清楚。应用机器学习算法对来自癌症基因组图谱数据库的转录组数据进行分析,以确定ccRCC患者的免疫表型和免疫特征。这些算法包括单样本基因集富集分析和细胞类型鉴定。利用生物信息学技术,我们研究了参与ccRCC免疫相互作用的免疫相关基因(IRG)的预后潜力和调控网络。确定了15个IRG(CCL7、CHGA、CMA1、CRABP2、IFNE、ISG15、NPR3、PDIA2、PGLYRP2、PLA2G2A、SAA1、TEK、TGFA、TNFSF14和UCN2)为与总生存期相关的预后IRG,并用于构建预后模型。1年时受试者工作特征曲线下面积为0.927;3年时为0.822;5年时为0.717,表明预测准确性良好。发现分子调控网络控制ccRCC中的免疫相互作用。此外,我们开发了一个包含该模型和具有高预后潜力的临床特征的列线图。通过系统研究ccRCC免疫相互作用的复杂调控机制、分子特征和预后潜力,我们为理解ccRCC的分子机制以及为未来研究确定新的预后标志物和治疗靶点提供了一个重要框架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/a38861cbafe7/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/dd3275ea85c3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/73fc5f1df9bf/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/c12295d19500/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/27aef08f2393/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/1573cd2fcc7e/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/d7ef92324584/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/075bd0e80fe7/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/a38861cbafe7/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/dd3275ea85c3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/73fc5f1df9bf/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/c12295d19500/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/27aef08f2393/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/1573cd2fcc7e/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/d7ef92324584/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/075bd0e80fe7/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4166/11379575/a38861cbafe7/gr8.jpg

相似文献

1
Prediction of clear cell renal cell carcinoma prognosis based on an immunogenomic landscape analysis.基于免疫基因组图谱分析的透明细胞肾细胞癌预后预测
Heliyon. 2024 Aug 13;10(16):e36156. doi: 10.1016/j.heliyon.2024.e36156. eCollection 2024 Aug 30.
2
Identification of a four immune-related genes signature based on an immunogenomic landscape analysis of clear cell renal cell carcinoma.基于透明细胞肾细胞癌免疫基因组景观分析的四个免疫相关基因特征的鉴定。
J Cell Physiol. 2020 Dec;235(12):9834-9850. doi: 10.1002/jcp.29796. Epub 2020 May 26.
3
A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in clear cell renal cell carcinoma.一种与透明细胞肾细胞癌的预后和免疫浸润格局相关的新型失巢凋亡相关预后特征。
Front Genet. 2022 Oct 19;13:1039465. doi: 10.3389/fgene.2022.1039465. eCollection 2022.
4
Clear cell renal cell carcinoma: immunological significance of alternative splicing signatures.透明细胞肾细胞癌:可变剪接特征的免疫学意义
Front Oncol. 2024 Jan 15;13:1206882. doi: 10.3389/fonc.2023.1206882. eCollection 2023.
5
Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma.肾透明细胞癌中免疫相关基因预后价值的开发与验证
Transl Androl Urol. 2021 Apr;10(4):1607-1619. doi: 10.21037/tau-20-1348.
6
Development of an Immune Prognostic Model for Clear Cell Renal Cell Carcinoma Based on Tumor Microenvironment.基于肿瘤微环境的肾透明细胞癌免疫预后模型的建立。
Horm Metab Res. 2023 Jun;55(6):402-412. doi: 10.1055/a-2079-2826. Epub 2023 May 16.
7
Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma.一种用于预测透明细胞肾细胞癌诊断、预后及药物治疗的新型5种铜死亡相关长链非编码RNA特征的开发与验证
Transl Androl Urol. 2023 Apr 28;12(4):622-641. doi: 10.21037/tau-23-65. Epub 2023 Apr 17.
8
SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma.SAA1 有望成为与细胞增殖、迁移相关的预后生物标志物,以及透明细胞肾细胞癌肿瘤微环境免疫浸润的指标。
Int J Mol Sci. 2023 Apr 19;24(8):7505. doi: 10.3390/ijms24087505.
9
Development and Validation of a Clinical Prognostic Model Based on Immune-Related Genes Expressed in Clear Cell Renal Cell Carcinoma.基于透明细胞肾细胞癌中表达的免疫相关基因的临床预后模型的开发与验证
Front Oncol. 2020 Aug 28;10:1496. doi: 10.3389/fonc.2020.01496. eCollection 2020.
10
Transcriptome mapping of renal clear cell carcinoma revealed by machine learning algorithm based on enhanced computed tomography images.基于增强 CT 图像的机器学习算法对肾透明细胞癌的转录组图谱分析。
J Gene Med. 2023 Jul;25(7):e3494. doi: 10.1002/jgm.3494. Epub 2023 May 2.

引用本文的文献

1
Integrative Analysis of Immune- and Metabolism-Related Genes Identifies Robust Prognostic Signature and PYCR1 as a Carcinogenic Regulator in Clear Cell Renal Cell Carcinoma.免疫与代谢相关基因的综合分析确定了透明细胞肾细胞癌中强大的预后特征以及作为致癌调节因子的PYCR1 。
Int J Mol Sci. 2025 May 21;26(10):4953. doi: 10.3390/ijms26104953.
2
Transcriptome analysis revealed a novel nine-gene prognostic risk score of clear cell renal cell carcinoma.转录组分析揭示了透明细胞肾细胞癌的一个新的九基因预后风险评分。
Medicine (Baltimore). 2024 Sep 27;103(39):e39678. doi: 10.1097/MD.0000000000039678.

本文引用的文献

1
Single cell deciphering of progression trajectories of the tumor ecosystem in head and neck cancer.单细胞解析头颈部癌症肿瘤生态系统的演进轨迹。
Nat Commun. 2024 Mar 22;15(1):2595. doi: 10.1038/s41467-024-46912-6.
2
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
3
First-line ICIs in renal cell carcinoma.一线免疫检查点抑制剂在肾细胞癌中的应用。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2225386. doi: 10.1080/21645515.2023.2225386. Epub 2023 Jul 3.
4
Update on combined immunotherapy for the treatment of advanced renal cell carcinoma.晚期肾细胞癌联合免疫治疗进展。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2193528. doi: 10.1080/21645515.2023.2193528. Epub 2023 Apr 16.
5
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.欧洲泌尿外科学会上尿路尿路上皮癌指南:2023 年更新版。
Eur Urol. 2023 Jul;84(1):49-64. doi: 10.1016/j.eururo.2023.03.013. Epub 2023 Mar 24.
6
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy.肿瘤浸润调节性T细胞作为癌症免疫治疗的靶点。
Cancer Cell. 2023 Mar 13;41(3):450-465. doi: 10.1016/j.ccell.2023.02.014.
7
Epidemiology of Renal Cell Carcinoma: 2022 Update.肾细胞癌的流行病学:2022 年更新。
Eur Urol. 2022 Nov;82(5):529-542. doi: 10.1016/j.eururo.2022.08.019. Epub 2022 Sep 10.
8
Inflammation: the incubator of the tumor microenvironment.炎症:肿瘤微环境的温床。
Trends Cancer. 2022 Nov;8(11):901-914. doi: 10.1016/j.trecan.2022.07.002. Epub 2022 Jul 28.
9
Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies.肿瘤相关巨噬细胞在癌症中的作用:癌症纳米免疫治疗的最新进展。
J Exp Clin Cancer Res. 2022 Feb 19;41(1):68. doi: 10.1186/s13046-022-02272-x.
10
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.髓源性抑制细胞作为癌症中免疫抑制调节因子及治疗靶点。
Signal Transduct Target Ther. 2021 Oct 7;6(1):362. doi: 10.1038/s41392-021-00670-9.